-
3 days ago | 
insidehealthpolicy.com | Jessica Karins |Maaisha Osman
HHS is set to announce Tuesday (April 22) an FDA effort to ban use of petroleum-based synthetic food dyes, the agency said, a major shift on food policy from the Trump administration that’s likely to meet with opposition from industry. HHS did not share details of the policy change but said HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary will announce it Tuesday at HHS’ headquarters, and added the plan will mark “a major step forward in...
-
1 week ago | 
insidehealthpolicy.com | Jessica Karins |Maaisha Osman
FDA will not allow experts who are employed by regulated industry to serve on advisory committees, the agency said in an announcement Thursday (April 17), but though the statement was framed as a change in policy, one expert said it was similar to FDA’s existing policy and so vague as to be “an announcement of nothing.” Another researcher, however, said the move come signal an attempt to add voices to advisory committees who are less qualified but ideologically aligned with...
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
A conservative think tank allied with President Donald Trump, the America First Policy Institute (AFPI), is calling on U.S. trade officials to take aim at foreign drug pricing policies that it says force Americans to shoulder the global burden of pharmaceutical innovation -- by using tariffs to force other countries to abandon what it calls “freeloading” practices.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
A conservative think tank allied with President Donald Trump, the America First Policy Institute (AFPI), is calling on U.S. trade officials to take aim at foreign drug pricing policies that it says force Americans to shoulder the global burden of pharmaceutical innovation -- by using tariffs to force other countries to abandon what it calls “freeloading” practices.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
HHS Secretary Robert F. Kennedy Jr. rejected the explanation that rising autism rates are due to better screening and diagnosis during a press conference Wednesday (April 16), instead calling the surge an “autism epidemic” driven by environmental exposures that he claims are regressing children and devastating families -- while accusing industries of profiting off toxins in air, medicine and food.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman |Jessica Karins
Although HHS Secretary Robert F. Kennedy Jr. avoided explicit suggestions that vaccines are associated with autism during a Wednesday (April 16) press conference, instead blaming environmental toxins, one industry expert speculated that he may be setting the stage for a broader campaign to link autism to vaccines -- starting with vague references to toxins in medicine, supporting sympathetic research, and eventually connecting the dots back to vaccines.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
President Donald Trump on Tuesday (April 15) signed an executive order that calls for increasing transparency and addressing a “statutory imbalance” in Medicare’s drug price negotiation program that it claims favors large molecule biologics over more widely used small molecule drugs -- signaling the administration may be sympathetic to the drug industry’s request for a so-called “pill fix” to the Inflation Reduction Act. The order directs HHS Secretary Robert F.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
President Donald Trump on Tuesday (April 15) signed an executive order aimed at lowering drug costs by accelerating FDA approvals of state importation programs, streamlining the review process for generics and biosimilars, and targeting pharmacy benefit manager (PBM) reforms affecting private plans -- though the order offers few details on how those initiatives will be carried out.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman
The Trump administration is preparing to slap tariffs on imported pharmaceuticals within the next month or two, Commerce Secretary Howard Lutnick said Sunday (April 13), citing national security concerns. The Association for Accessible Medicines (AAM), which represents generic and biosimilar drug manufacturers, pushed back Monday (April 14) on the plan, warning it could deepen existing drug shortages, raise prices and harm patient access.
-
1 week ago | 
insidehealthpolicy.com | Maaisha Osman |Donna Haseley
HHS Secretary Robert F. Kennedy Jr. doubled down on his calls for a radical transformation of government health agencies, telling FDA staff Friday ( April 11) the agency has become a “sock puppet” of the industries it regulates and urging them to resist the “deep state,” according to a recording obtained by media outlets, capping off a tumultuous week that included a key public health group’s call for Kennedy’s resignation and a duo of Journal of the American Medical Association...
